A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalating Parallel-Group Study to Investigate the Tolerability of Enecadin (INN) in Acute Ischemic Stroke.

Trial Profile

A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Dose-Escalating Parallel-Group Study to Investigate the Tolerability of Enecadin (INN) in Acute Ischemic Stroke.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 May 2014

At a glance

  • Drugs Enecadin (Primary)
  • Indications Stroke
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms TEST
  • Sponsors PAION
  • Most Recent Events

    • 21 May 2014 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
    • 14 Nov 2007 Status change
    • 03 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top